EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study

Agnès Calsina-Berna, Jesús González-Barboteo, Anna Esteve, Silvia Llorens Torromé, Gemma Sanclemente Juarros, Montserrat Bleda Pérez, Irene Carré Miranda, Margarita Alvaro Pardo, Lina Maria Nitola Mendoza, Paula Garrido Ballart, Roser Cuadros-Margarit, Montse Olmo Plaza und 7 weitere

Supportive Care in Cancer · 2026-02 · 34 (2)

DOI: 10.1007/s00520-025-10311-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Supportive Care in Cancer, online erschienen am 11.01.2026. Verfasst von Agnès Calsina-Berna und 18 weiteren Autor:innen. Beteiligte Einrichtung: Palliative Care Department, Research and Knowledge Group in Palliative Care of Catalan Institute of Oncology (GRICOPAL), Institut Català d'Oncologia-…. Hauptthemen laut MEDLINE: Methadone, Analgesics, Opioid, Cancer Pain, Neurotoxicity Syndromes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: To describe the frequency of opioid-induced neurotoxicity (OINT) after opioid conversion (OC) to methadone using the Stop-and-Go (SAG) method in cancer patients with inadequate pain control, and to identify factors associated with OINT. METHODS: This multicenter retrospective cohort study included adult hospitalized cancer patients who underwent OC to methadone using the SAG method for poor pain control at two comprehensive cancer centers between January 2018 and October 2022. Patients were monitored 14 days after OC, and variables related to OINT were analyzed. Ethical approval was obtained. RESULTS: A total of 372 patients underwent OC using the SAG method. The mean morphine-equivalent daily dose (MEDD) before OC was 212.2 mg (SD 128). OINT occurred in 70 patients (18.8%). Methadone was permanently discontinued in 2 patients (2.8%) and temporarily withheld in 7, while 61 were managed with hydration and a 15-20% methadone dose reduction. No patient required naloxone. OINT was less frequent in younger patients (mean age 59.4 vs. 63 years; p = 0.032) and showed a trend toward lower incidence in women (13% vs.22%; p = 0.065). Preexisting cognitive impairment or delirium was associated with OINT (52.4% vs.16.8%; p < 0.001). The mean time from OC to death was shorter among patients with OINT (2.1 months; SD 3.9) compared with those without OINT (3.6 months; SD 6.4; p = 0.012). CONCLUSION: OC to methadone using the SAG method in patients with low-to-moderate MEDD was associated with a relatively low OINT frequency (18.8%). These findings suggest that SAG method in patients with low-to-moderate MEDD before OC may be safe, particularly for younger patients and those without cognitive impairment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethadoneAnalgesics, OpioidCancer PainNeurotoxicity SyndromesHumansRetrospective StudiesFemaleMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

Adverse effectsCancer painConversionMethadoneToxicity

Substanzen

MethadoneAnalgesics, Opioid

Autor:innen und Institutionen

  • Palliative Care Department, Research and Knowledge Group in Palliative Care of Catalan Institute of Oncology (GRICOPAL), Institut Català d'Oncologia-Badalona, Badalona, Spain.
  • Faculty of Medicine, University of Vic-Central University of Catalonia, UVic-UCC, Vic/Manresa, Catalonia, Spain.
  • Faculty of Medicine, University of Vic-Central University of Catalonia, UVic-UCC, Vic/Manresa, Catalonia, Spain. jgonzalez@iconcologia.net.
  • Palliative Care Department, Research and Knowledge Group in Palliative Care of Catalan Institute of Oncology (GRICOPAL), Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain. jgonzalez@iconcologia.net.
  • Institut Català d'Oncologia ICO, Medical Oncology Service, Badalona Applied Research Group in Oncology B-ARGO/CARE program, IGTP, Hospital Germans Trias i Pujol, Badalona, Spain.
  • Palliative Care Department, Research and Knowledge Group in Palliative Care of Catalan Institute of Oncology (GRICOPAL), Institut Català d'Oncologia L'Hospitalet, Barcelona, Spain.

Zitieren

APA

Calsina-Berna, A., González-Barboteo, J., Esteve, A., Llorens Torromé, S., Sanclemente Juarros, G., Bleda Pérez, M., Carré Miranda, I., Alvaro Pardo, M., Maria Nitola Mendoza, L., Garrido Ballart, P., Cuadros-Margarit, R., Olmo Plaza, M., Andrea Cruz Sequeiros, C., Labori Trias, M., Cuenca-Casbas, P., Bavestrello, P., Alcalde Rodrigo, M., Borque Roda, I., & Julià-Torras, J. (2026). Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study. Supportive Care in Cancer, 34(2). https://doi.org/10.1007/s00520-025-10311-4

Vancouver

Calsina-Berna A, González-Barboteo J, Esteve A, Llorens Torromé S, Sanclemente Juarros G, Bleda Pérez M, et al. Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study. Supportive Care in Cancer. 2026;34(2). doi:10.1007/s00520-025-10311-4

BibTeX
@article{CalsinaBerna2026,
  author = {Calsina-Berna, Agnès and González-Barboteo, Jesús and Esteve, Anna and Llorens Torromé, Silvia and Sanclemente Juarros, Gemma and Bleda Pérez, Montserrat and Carré Miranda, Irene and Alvaro Pardo, Margarita and Maria Nitola Mendoza, Lina and Garrido Ballart, Paula and Cuadros-Margarit, Roser and Olmo Plaza, Montse and Andrea Cruz Sequeiros, Claudia and Labori Trias, Maria and Cuenca-Casbas, Paula and Bavestrello, Pierluigi and Alcalde Rodrigo, Maria and Borque Roda, Ignacio and Julià-Torras, Joaquim},
  title = {Opioid-induced neurotoxicity after opioid conversion to methadone in patients with cancer pain using the stop-and-go method: A multicenter retrospective cohort study},
  journal = {Supportive Care in Cancer},
  year = {2026},
  volume = {34},
  number = {2},
  doi = {10.1007/s00520-025-10311-4}
}
Kostenlos starten →